RIPK1 inhibition enhanced the therapeutic efficacy of the HDAC inhibitor chidamide in FLT3-ITD positive AML, both in vitro and in vivo[111,112] and increased the efficacy of differentiating agents[113]. The gene discussed is FLT3; the disease is acute myeloid leukemia.